A subgroup comparison showed larger numerical differences favoring nivolumab plus ipilimumab in acral melanoma and BRAF-mutant melanomas; nivolumab plus ralatlimab was associated with lower grade 3-4 adverse events compared to nivolumab plus ipilimumab [110]. The gene discussed is BRAF; the disease is melanoma.